{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:18:58Z","timestamp":1788787138376,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,3,10]],"date-time":"2012-03-10T00:00:00Z","timestamp":1331337600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2012,3,10]],"date-time":"2012-03-10T00:00:00Z","timestamp":1331337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Increased frequencies of hyperuricemia and gout have been associated with primary hyperparathyroidism, and recent clinical trials of parathyroid hormone (PTH) have reported hyperuricemic adverse events. We evaluated the potential population impact of PTH on serum uric acid (SUA) levels by using a nationally representative sample of United States adults.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>By using data from 8,316 participants aged 18 years and older in the National Health and Nutrition Examination Survey 2003 to 2006, we examined the relation between serum PTH and SUA levels with weighted linear regression. Additionally, we examined the relation with hyperuricemia by using weighted logistic regression.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>SUA levels increased with increasing serum PTH concentration. After adjusting for age, sex, dietary factors, glomerular filtration rate (GFR), and other potentially related biomarkers (calcium, phosphorus, alkaline-phosphatase, 25-hydroxyvitamin D), the SUA level differences from the bottom (referent) to top quintiles of serum PTH levels were 0, 8, 13, 14, and 19 \u03bc<jats:italic>M<\/jats:italic> (95% CI, 12 to 26; <jats:italic>P<\/jats:italic> for trend, &lt; 0.001). These estimates were larger among renally impaired individuals (multivariate SUA difference between the extreme quintiles of PTH, 26 versus 15 \u03bc<jats:italic>M<\/jats:italic> among those with GFR \u2265 60 versus &lt; 60 ml\/min per 1.73 m<jats:sup>2<\/jats:sup>, respectively) (<jats:italic>P<\/jats:italic> for interaction = 0.004). The odds of hyperuricemia by various definitions increased with increasing PTH levels as well (multivariate <jats:italic>P<\/jats:italic> values for trend, &lt; 0.05).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>These nationally representative data indicate that serum PTH levels are independently associated with serum uric acid levels and the frequency of hyperuricemia at the population level.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar3769","type":"journal-article","created":{"date-parts":[[2012,3,10]],"date-time":"2012-03-10T07:14:06Z","timestamp":1331363646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["The independent association between parathyroid hormone levels and hyperuricemia: a national population study"],"prefix":"10.1186","volume":"14","author":[{"given":"Janet Y","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Woong J","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Mount","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon K","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,10]]},"reference":[{"key":"3533_CR1","unstructured":"Zhu Y, Pandya BJ, Choi HK: Comorbidities of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Am J Med."},{"key":"3533_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1056\/NEJM196107202650302","volume":"265","author":"DH Mintz","year":"1961","unstructured":"Mintz DH, Canary JJ, Carreon G, Kyle LH: Hyperuricemia in hyperparathyroidism. N Engl J Med. 1961, 265: 112-115. 10.1056\/NEJM196107202650302.","journal-title":"N Engl J Med"},{"key":"3533_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.7326\/0003-4819-79-4-566","volume":"79","author":"Clinical conference","year":"1973","unstructured":"Clinical conference: Hyperparathyroidism: recent studies. Ann Intern Med. 1973, 79: 566-581.","journal-title":"Ann Intern Med"},{"key":"3533_CR4","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1136\/bmj.281.6249.1164","volume":"281","author":"JT Scott","year":"1980","unstructured":"Scott JT: Long-term management of gout and hyperuricaemia. Br Med J. 1980, 281: 1164-1166. 10.1136\/bmj.281.6249.1164.","journal-title":"Br Med J"},{"key":"3533_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0009-8981(77)90147-4","volume":"80","author":"T Christensson","year":"1977","unstructured":"Christensson T: Serum urate in subjects with hypercalcaemic hyperparathyroidism. Clin Chim Acta. 1977, 80: 529-533. 10.1016\/0009-8981(77)90147-4.","journal-title":"Clin Chim Acta"},{"key":"3533_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00005792-197403000-00002","volume":"53","author":"LE Mallette","year":"1974","unstructured":"Mallette LE, Bilezikian JP, Heath DA, Aurbach GD: Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore). 1974, 53: 127-146.","journal-title":"Medicine (Baltimore)"},{"key":"3533_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2169\/internalmedicine.31.807","volume":"31","author":"I Hisatome","year":"1992","unstructured":"Hisatome I, Ishimura M, Sasaki N, Yamakawa M, Kosaka H, Tanaka Y, Kouchi T, Mitani Y, Yoshida A, Kotake H, Shigemasa C, Mashiba H: Renal handling of urate in two patients with hyperuricemia and primary hyperparathyroidism. Intern Med. 1992, 31: 807-811. 10.2169\/internalmedicine.31.807.","journal-title":"Intern Med"},{"key":"3533_CR8","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001, 344: 1434-1441. 10.1056\/NEJM200105103441904.","journal-title":"N Engl J Med"},{"key":"3533_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","volume":"18","author":"PD Miller","year":"2007","unstructured":"Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH: Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007, 18: 59-68. 10.1007\/s00198-006-0189-8.","journal-title":"Osteoporos Int"},{"key":"3533_CR10","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007, 357: 2028-2039. 10.1056\/NEJMoa071408.","journal-title":"N Engl J Med"},{"key":"3533_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/rheumatology\/ken416","volume":"48","author":"N Dalbeth","year":"2009","unstructured":"Dalbeth N, Horne A, Gamble GD, Ames R, Mason B, McQueen FM, Bolland MJ, Grey A, Reid IR: The effect of calcium supplementation on serum urate: analysis of a randomized controlled trial. Rheumatology (Oxford). 2009, 48: 195-197.","journal-title":"Rheumatology (Oxford)"},{"key":"3533_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/jbmr.286","volume":"26","author":"I Nabipour","year":"2011","unstructured":"Nabipour I, Sambrook PN, Blyth FM, Janu MR, Waite LM, Naganathan V, Handelsman DJ, Le Couteur DG, Cumming RG, Seibel MJ: Serum uric acid is associated with bone health in older men: a cross-sectional population-based study. J Bone Miner Res. 2011, 26: 955-964. 10.1002\/jbmr.286.","journal-title":"J Bone Miner Res"},{"key":"3533_CR13","unstructured":"NHANES: About the National Health and Nutrition Examination Survery. [http:\/\/www.cdc.gov\/nchs\/nhanes\/about_nhanes.htm]"},{"key":"3533_CR14","unstructured":"NHANES: NHANES 2005-2006 - Lab Methods. [http:\/\/www.cdc.gov\/nchs\/nhanes\/nhanes2005-2006\/lab_methods_05_06.htm]"},{"key":"3533_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.7326\/0003-4819-141-2-200407200-00007","volume":"141","author":"CY Hsu","year":"2004","unstructured":"Hsu CY, Vittinghoff E, Lin F, Shlipak MG: The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med. 2004, 141: 95-101.","journal-title":"Ann Intern Med"},{"key":"3533_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999, 130: 461-470.","journal-title":"Ann Intern Med"},{"key":"3533_CR17","first-page":"155A","volume":"11","author":"AS Levey","year":"2000","unstructured":"Levey AS, Greene T, Kusek JW, Beck GJ: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol. 2000, 11: 155A-","journal-title":"J Am Soc Nephrol"},{"key":"3533_CR18","volume-title":"NHANES III 1988-94 Reference Manuals and Reports (on CD-ROM)","author":"Centers for Disease Control and Prevention","year":"1996","unstructured":"Centers for Disease Control and Prevention: NHANES III 1988-94 Reference Manuals and Reports (on CD-ROM). 1996, Hyattsville, Md: National Center for Health Statistics"},{"key":"3533_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/art.20761","volume":"52","author":"HK Choi","year":"2005","unstructured":"Choi HK, Liu S, Curhan G: Intake of purine-rich foods, protein, dairy products, and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005, 52: 283-289. 10.1002\/art.20761.","journal-title":"Arthritis Rheum"},{"key":"3533_CR20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJMoa035700","volume":"350","author":"HK Choi","year":"2004","unstructured":"Choi HK, Atkinson K, Karlson EW, Willett WC, Curhan G: Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004, 350: 1093-1103. 10.1056\/NEJMoa035700.","journal-title":"N Engl J Med"},{"key":"3533_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/BOR.0b013e32833645e8","volume":"22","author":"HK Choi","year":"2010","unstructured":"Choi HK, Zhu Y, Mount DB: Genetics of gout. Curr Opin Rheumatol. 2010, 22: 144-151. 10.1097\/BOR.0b013e32833645e8.","journal-title":"Curr Opin Rheumatol"},{"key":"3533_CR22","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1172\/JCI42344","volume":"120","author":"A So","year":"2010","unstructured":"So A, Thorens B: Uric acid transport and disease. J Clin Invest. 2010, 120: 1791-1799. 10.1172\/JCI42344.","journal-title":"J Clin Invest"},{"key":"3533_CR23","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/ki.2010.206","volume":"78","author":"AF Wright","year":"2010","unstructured":"Wright AF, Rudan I, Hastie ND, Campbell H: A \"complexity\" of urate transporters. Kidney Int. 2010, 78: 446-452. 10.1038\/ki.2010.206.","journal-title":"Kidney Int"},{"key":"3533_CR24","doi-asserted-by":"publisher","first-page":"e1000504","DOI":"10.1371\/journal.pgen.1000504","volume":"5","author":"M Kolz","year":"2009","unstructured":"Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, Johansson A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S, Bochud M, Brown M, Campbell H, EUROSPAN Consortium, Connell J, Dominiczak A, Homuth G, Lamina C, McCarthy MI, ENGAGE Consortium, Meitinger T, Mooser V, Munroe P, Nauck M, Peden J, et al: Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009, 5: e1000504-10.1371\/journal.pgen.1000504.","journal-title":"PLoS Genet"},{"key":"3533_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/jama.1993.03510030078038","volume":"270","author":"FP Cappuccio","year":"1993","unstructured":"Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M: Uric acid metabolism and tubular sodium handling: results from a population-based study. JAMA. 1993, 270: 354-359. 10.1001\/jama.1993.03510030078038.","journal-title":"JAMA"},{"key":"3533_CR26","doi-asserted-by":"publisher","first-page":"31601","DOI":"10.1074\/jbc.M000600200","volume":"275","author":"R Collazo","year":"2000","unstructured":"Collazo R, Fan L, Hu MC, Zhao H, Wiederkehr MR, Moe OW: Acute regulation of Na+\/H+ exchanger NHE3 by parathyroid hormone via NHE3 phosphorylation and dynamin-dependent endocytosis. J Biol Chem. 2000, 275: 31601-31608.","journal-title":"J Biol Chem"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3769.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar3769\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3769.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:29:49Z","timestamp":1728383389000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar3769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,10]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,4]]}},"alternative-id":["3533"],"URL":"https:\/\/doi.org\/10.1186\/ar3769","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,10]]},"assertion":[{"value":"13 November 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R56"}}